Investigation of an Mpox Outbreak Affecting Many Vaccinated Persons in Chicago, Illinois—March 2023–June 2023
Open Access
- 3 April 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (1) , 122-129
Abstract
Background: After months of few mpox cases, an increase in cases was reported in Chicago during May 2023, predominantly among fully vaccinated (FV) patients. We investigated the outbreak scope, differences between vaccinated and unvaccinated patients, and hypotheses for monkeypox virus (MPXV) infection after vaccination. Methods: We interviewed patients and reviewed medical records to assess demographic, behavioral, and clinical characteristics; mpox vaccine status; and vaccine administration routes. We evaluated serum antibody levels after infection and compared patient viral genomes with MPXV sequences in available databases. We discussed potential vaccine compromise with partners who manufactured, handled, and administered the vaccine associated with breakthrough infections. Results: During 18 March–27 June 2023, we identified 49 mpox cases; 57% of these mpox patients were FV. FV patients received both JYNNEOS doses subcutaneously (57%), intradermally (7%), or via heterologous administration (36%). FV patients had more median sex partners (3; interquartile range [IQR] = 1–4) versus not fully vaccinated patients (1; IQR = 1–2). Thirty-six of 37 sequenced specimens belonged to lineage B.1.20 of clade IIb MPXV, which did not demonstrate any amino acid changes relative to B.1, the predominant lineage from May 2022. Vaccinated patients demonstrated expected humoral antibody responses; none were hospitalized. No vaccine storage excursions were identified. Approximately 63% of people at risk for mpox in Chicago were FV during this period. Conclusions: Our investigation indicated that cases were likely due to frequent behaviors associated with mpox transmission, even with relatively high vaccine effectiveness and vaccine coverage. Cases after vaccination might occur in similar populations.Keywords
Funding Information
- US Government
This publication has 25 references indexed in Scilit:
- Mpox breakthrough infections: concerns and actionsThe Lancet Infectious Diseases, 2023
- Mpox in people with past infection or a complete vaccination course: a global case seriesThe Lancet Infectious Diseases, 2023
- Molecular phylogenomic analysis reveals a single origin of monkeypox virus transmission in Guangzhou, China in June 2023Biosafety and Health, 2023
- Extragenital gonorrhoea, chlamydia, and HIV co-infection in people with mpoxThe Lancet Infectious Diseases, 2023
- Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United StatesNew England Journal of Medicine, 2023
- Resurgence of symptomatic Mpox among vaccinated patients: First clues from a new-onset local clusterInfectious Diseases Now, 2023
- Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational studyThe Lancet Infectious Diseases, 2023
- Real-world effectiveness of a single dose of mpox vaccine in malesNature Medicine, 2023
- Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of CongoVaccine, 2022
- Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022New England Journal of Medicine, 2022